Positioning Therapies in GI Disorders
This activity has been designed to meet the educational needs of healthcare providers involved in the care of patients with gastrointestinal disorders.
This supplement summarizes the key points of each discussion, with the aim of providing a snapshot of best practices for managing GI disorders in real world practice in the context of evolving clinical guidelines and an ever-expanding therapeutic landscape.
Upon completion of this activity, participants should be able to:
Describe evolving patient management and treatment strategies for CLD and GI disorders
Integrate significant advances in therapeutic and diagnostic modalities into clinical practice
Apply the latest clinical research, including future therapies and their role in the context of the current clinical paradigm
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and the Gi Health Foundation. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, the University of Cincinnati staff and the Gi Health Foundation staff have no relationships to disclose.
Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
The opinions expressed during the activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
Supported by an educational grant from AbbVie, Janssen Biotech, Inc., Pfizer Inc., Phathom Pharmaceuticals, Salix Pharmaceuticals, and Takeda Pharmaceuticals U.S.A., Inc.
This activity is jointly provided by the University of Cincinnati and the Gi Health Foundation.